nodes	percent_of_prediction	percent_of_DWPC	metapath
Dolutegravir—UGT1A1—Sorafenib—thyroid cancer	0.596	1	CbGbCtD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—TCF7L1—thyroid cancer	0.034	0.216	CbGpPWpGaD
Dolutegravir—POU2F2—Ectoderm Differentiation—TRIM33—thyroid cancer	0.0215	0.137	CbGpPWpGaD
Dolutegravir—Musculoskeletal disorder—Vandetanib—thyroid cancer	0.019	0.0773	CcSEcCtD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—RET—thyroid cancer	0.0152	0.0963	CbGpPWpGaD
Dolutegravir—POU2F2—Ectoderm Differentiation—TCF7L1—thyroid cancer	0.0144	0.0911	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—THRB—thyroid cancer	0.0141	0.0895	CbGpPWpGaD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—NRG1—thyroid cancer	0.0135	0.0859	CbGpPWpGaD
Dolutegravir—Serum creatinine increased—Vandetanib—thyroid cancer	0.011	0.0449	CcSEcCtD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—PRKAR1A—thyroid cancer	0.00938	0.0595	CbGpPWpGaD
Dolutegravir—Bilirubin total increased—Epirubicin—thyroid cancer	0.00844	0.0343	CcSEcCtD
Dolutegravir—Bilirubin total increased—Doxorubicin—thyroid cancer	0.00781	0.0317	CcSEcCtD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—SST—thyroid cancer	0.00741	0.047	CbGpPWpGaD
Dolutegravir—Blood bilirubin increased—Vandetanib—thyroid cancer	0.00718	0.0292	CcSEcCtD
Dolutegravir—POU2F2—BCR signaling pathway—PTEN—thyroid cancer	0.00511	0.0324	CbGpPWpGaD
Dolutegravir—Blood bilirubin increased—Sorafenib—thyroid cancer	0.00485	0.0197	CcSEcCtD
Dolutegravir—Blood creatinine increased—Vandetanib—thyroid cancer	0.00462	0.0188	CcSEcCtD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—HIF1A—thyroid cancer	0.00445	0.0282	CbGpPWpGaD
Dolutegravir—Alanine aminotransferase increased—Vandetanib—thyroid cancer	0.00435	0.0177	CcSEcCtD
Dolutegravir—Opportunistic infection—Epirubicin—thyroid cancer	0.00421	0.0171	CcSEcCtD
Dolutegravir—Neutropenia—Vandetanib—thyroid cancer	0.00399	0.0162	CcSEcCtD
Dolutegravir—Opportunistic infection—Doxorubicin—thyroid cancer	0.00389	0.0158	CcSEcCtD
Dolutegravir—Hyperglycaemia—Vandetanib—thyroid cancer	0.00385	0.0156	CcSEcCtD
Dolutegravir—Renal failure—Vandetanib—thyroid cancer	0.00374	0.0152	CcSEcCtD
Dolutegravir—Hepatobiliary disease—Vandetanib—thyroid cancer	0.0036	0.0146	CcSEcCtD
Dolutegravir—Myositis—Epirubicin—thyroid cancer	0.00345	0.014	CcSEcCtD
Dolutegravir—Urinary tract disorder—Vandetanib—thyroid cancer	0.00337	0.0137	CcSEcCtD
Dolutegravir—Urethral disorder—Vandetanib—thyroid cancer	0.00335	0.0136	CcSEcCtD
Dolutegravir—POU2F2—BCR signaling pathway—HRAS—thyroid cancer	0.00333	0.0211	CbGpPWpGaD
Dolutegravir—Myositis—Doxorubicin—thyroid cancer	0.0032	0.013	CcSEcCtD
Dolutegravir—UGT1A1—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.00308	0.0195	CbGpPWpGaD
Dolutegravir—Abdominal pain upper—Sorafenib—thyroid cancer	0.00304	0.0124	CcSEcCtD
Dolutegravir—Mental disorder—Vandetanib—thyroid cancer	0.00299	0.0122	CcSEcCtD
Dolutegravir—POU2F2—BCR signaling pathway—AKT1—thyroid cancer	0.00294	0.0187	CbGpPWpGaD
Dolutegravir—Alanine aminotransferase increased—Sorafenib—thyroid cancer	0.00293	0.0119	CcSEcCtD
Dolutegravir—Abdominal discomfort—Sorafenib—thyroid cancer	0.00276	0.0112	CcSEcCtD
Dolutegravir—Serum creatinine increased—Epirubicin—thyroid cancer	0.00275	0.0112	CcSEcCtD
Dolutegravir—UGT1A1—Metapathway biotransformation—CHST14—thyroid cancer	0.00271	0.0172	CbGpPWpGaD
Dolutegravir—Neutropenia—Sorafenib—thyroid cancer	0.00269	0.0109	CcSEcCtD
Dolutegravir—Serum creatinine increased—Doxorubicin—thyroid cancer	0.00255	0.0104	CcSEcCtD
Dolutegravir—Renal failure—Sorafenib—thyroid cancer	0.00252	0.0102	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00251	0.0102	CcSEcCtD
Dolutegravir—Hepatobiliary disease—Sorafenib—thyroid cancer	0.00243	0.00986	CcSEcCtD
Dolutegravir—Nervous system disorder—Vandetanib—thyroid cancer	0.00238	0.00966	CcSEcCtD
Dolutegravir—Skin disorder—Vandetanib—thyroid cancer	0.00236	0.00957	CcSEcCtD
Dolutegravir—Urinary tract disorder—Sorafenib—thyroid cancer	0.00227	0.00924	CcSEcCtD
Dolutegravir—Urethral disorder—Sorafenib—thyroid cancer	0.00226	0.00917	CcSEcCtD
Dolutegravir—Insomnia—Vandetanib—thyroid cancer	0.00219	0.00891	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00209	0.00851	CcSEcCtD
Dolutegravir—Fatigue—Vandetanib—thyroid cancer	0.00209	0.0085	CcSEcCtD
Dolutegravir—Immune system disorder—Sorafenib—thyroid cancer	0.00208	0.00845	CcSEcCtD
Dolutegravir—Mental disorder—Sorafenib—thyroid cancer	0.00202	0.0082	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00198	0.00806	CcSEcCtD
Dolutegravir—Abdominal pain—Vandetanib—thyroid cancer	0.00192	0.00779	CcSEcCtD
Dolutegravir—Blood bilirubin increased—Epirubicin—thyroid cancer	0.00179	0.00728	CcSEcCtD
Dolutegravir—Inflammation—Epirubicin—thyroid cancer	0.00175	0.0071	CcSEcCtD
Dolutegravir—Asthenia—Vandetanib—thyroid cancer	0.00174	0.00707	CcSEcCtD
Dolutegravir—Pruritus—Vandetanib—thyroid cancer	0.00172	0.00697	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00169	0.00689	CcSEcCtD
Dolutegravir—Abnormal dreams—Epirubicin—thyroid cancer	0.00167	0.00681	CcSEcCtD
Dolutegravir—Diarrhoea—Vandetanib—thyroid cancer	0.00166	0.00674	CcSEcCtD
Dolutegravir—Blood bilirubin increased—Doxorubicin—thyroid cancer	0.00166	0.00674	CcSEcCtD
Dolutegravir—Inflammation—Doxorubicin—thyroid cancer	0.00162	0.00657	CcSEcCtD
Dolutegravir—Nervous system disorder—Sorafenib—thyroid cancer	0.0016	0.00652	CcSEcCtD
Dolutegravir—Dizziness—Vandetanib—thyroid cancer	0.0016	0.00652	CcSEcCtD
Dolutegravir—Skin disorder—Sorafenib—thyroid cancer	0.00159	0.00646	CcSEcCtD
Dolutegravir—Abnormal dreams—Doxorubicin—thyroid cancer	0.00155	0.0063	CcSEcCtD
Dolutegravir—Vomiting—Vandetanib—thyroid cancer	0.00154	0.00627	CcSEcCtD
Dolutegravir—Rash maculo-papular—Epirubicin—thyroid cancer	0.00154	0.00626	CcSEcCtD
Dolutegravir—Rash—Vandetanib—thyroid cancer	0.00153	0.00621	CcSEcCtD
Dolutegravir—Dermatitis—Vandetanib—thyroid cancer	0.00153	0.00621	CcSEcCtD
Dolutegravir—Headache—Vandetanib—thyroid cancer	0.00152	0.00617	CcSEcCtD
Dolutegravir—Nausea—Vandetanib—thyroid cancer	0.00144	0.00585	CcSEcCtD
Dolutegravir—Rash maculo-papular—Doxorubicin—thyroid cancer	0.00142	0.00579	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00141	0.00574	CcSEcCtD
Dolutegravir—Fatigue—Sorafenib—thyroid cancer	0.00141	0.00573	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00134	0.00544	CcSEcCtD
Dolutegravir—Abdominal pain—Sorafenib—thyroid cancer	0.00129	0.00525	CcSEcCtD
Dolutegravir—Renal impairment—Epirubicin—thyroid cancer	0.00129	0.00525	CcSEcCtD
Dolutegravir—Hypersensitivity—Sorafenib—thyroid cancer	0.0012	0.0049	CcSEcCtD
Dolutegravir—Renal impairment—Doxorubicin—thyroid cancer	0.0012	0.00486	CcSEcCtD
Dolutegravir—Asthenia—Sorafenib—thyroid cancer	0.00117	0.00477	CcSEcCtD
Dolutegravir—Pruritus—Sorafenib—thyroid cancer	0.00116	0.0047	CcSEcCtD
Dolutegravir—Blood creatinine increased—Epirubicin—thyroid cancer	0.00115	0.00468	CcSEcCtD
Dolutegravir—Abdominal pain upper—Epirubicin—thyroid cancer	0.00112	0.00457	CcSEcCtD
Dolutegravir—Diarrhoea—Sorafenib—thyroid cancer	0.00112	0.00455	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—SLC5A5—thyroid cancer	0.00109	0.0069	CbGpPWpGaD
Dolutegravir—Alanine aminotransferase increased—Epirubicin—thyroid cancer	0.00108	0.00441	CcSEcCtD
Dolutegravir—Dizziness—Sorafenib—thyroid cancer	0.00108	0.0044	CcSEcCtD
Dolutegravir—Blood creatinine increased—Doxorubicin—thyroid cancer	0.00107	0.00433	CcSEcCtD
Dolutegravir—Vomiting—Sorafenib—thyroid cancer	0.00104	0.00423	CcSEcCtD
Dolutegravir—Abdominal pain upper—Doxorubicin—thyroid cancer	0.00104	0.00422	CcSEcCtD
Dolutegravir—Rash—Sorafenib—thyroid cancer	0.00103	0.00419	CcSEcCtD
Dolutegravir—Dermatitis—Sorafenib—thyroid cancer	0.00103	0.00419	CcSEcCtD
Dolutegravir—Headache—Sorafenib—thyroid cancer	0.00102	0.00416	CcSEcCtD
Dolutegravir—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	0.001	0.00408	CcSEcCtD
Dolutegravir—Neutropenia—Epirubicin—thyroid cancer	0.000994	0.00404	CcSEcCtD
Dolutegravir—Nausea—Sorafenib—thyroid cancer	0.000971	0.00395	CcSEcCtD
Dolutegravir—Hyperglycaemia—Epirubicin—thyroid cancer	0.000959	0.0039	CcSEcCtD
Dolutegravir—Renal failure—Epirubicin—thyroid cancer	0.000932	0.00379	CcSEcCtD
Dolutegravir—Neutropenia—Doxorubicin—thyroid cancer	0.00092	0.00374	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—RXRA—thyroid cancer	0.000914	0.00579	CbGpPWpGaD
Dolutegravir—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000896	0.00364	CcSEcCtD
Dolutegravir—Hyperglycaemia—Doxorubicin—thyroid cancer	0.000887	0.00361	CcSEcCtD
Dolutegravir—Renal failure—Doxorubicin—thyroid cancer	0.000862	0.0035	CcSEcCtD
Dolutegravir—Hepatitis—Epirubicin—thyroid cancer	0.000851	0.00346	CcSEcCtD
Dolutegravir—Urinary tract disorder—Epirubicin—thyroid cancer	0.00084	0.00341	CcSEcCtD
Dolutegravir—Urethral disorder—Epirubicin—thyroid cancer	0.000834	0.00339	CcSEcCtD
Dolutegravir—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.000829	0.00337	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—RXRA—thyroid cancer	0.000801	0.00508	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—NRG1—thyroid cancer	0.00079	0.00501	CbGpPWpGaD
Dolutegravir—Hepatitis—Doxorubicin—thyroid cancer	0.000787	0.0032	CcSEcCtD
Dolutegravir—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000777	0.00316	CcSEcCtD
Dolutegravir—Urethral disorder—Doxorubicin—thyroid cancer	0.000772	0.00314	CcSEcCtD
Dolutegravir—Immune system disorder—Epirubicin—thyroid cancer	0.000768	0.00312	CcSEcCtD
Dolutegravir—Mental disorder—Epirubicin—thyroid cancer	0.000745	0.00303	CcSEcCtD
Dolutegravir—Flatulence—Epirubicin—thyroid cancer	0.00073	0.00297	CcSEcCtD
Dolutegravir—Immune system disorder—Doxorubicin—thyroid cancer	0.000711	0.00289	CcSEcCtD
Dolutegravir—Mental disorder—Doxorubicin—thyroid cancer	0.00069	0.0028	CcSEcCtD
Dolutegravir—Flatulence—Doxorubicin—thyroid cancer	0.000675	0.00274	CcSEcCtD
Dolutegravir—Vertigo—Epirubicin—thyroid cancer	0.000665	0.0027	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000626	0.00255	CcSEcCtD
Dolutegravir—Vertigo—Doxorubicin—thyroid cancer	0.000616	0.0025	CcSEcCtD
Dolutegravir—Nervous system disorder—Epirubicin—thyroid cancer	0.000593	0.00241	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—MINPP1—thyroid cancer	0.000589	0.00373	CbGpPWpGaD
Dolutegravir—Skin disorder—Epirubicin—thyroid cancer	0.000587	0.00239	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000579	0.00235	CcSEcCtD
Dolutegravir—Nervous system disorder—Doxorubicin—thyroid cancer	0.000548	0.00223	CcSEcCtD
Dolutegravir—Insomnia—Epirubicin—thyroid cancer	0.000547	0.00222	CcSEcCtD
Dolutegravir—Skin disorder—Doxorubicin—thyroid cancer	0.000543	0.00221	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000522	0.00212	CcSEcCtD
Dolutegravir—Fatigue—Epirubicin—thyroid cancer	0.000521	0.00212	CcSEcCtD
Dolutegravir—Insomnia—Doxorubicin—thyroid cancer	0.000506	0.00206	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—NDUFA13—thyroid cancer	0.000501	0.00317	CbGpPWpGaD
Dolutegravir—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000494	0.00201	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000483	0.00196	CcSEcCtD
Dolutegravir—Fatigue—Doxorubicin—thyroid cancer	0.000482	0.00196	CcSEcCtD
Dolutegravir—Abdominal pain—Epirubicin—thyroid cancer	0.000478	0.00194	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—CHST14—thyroid cancer	0.000471	0.00298	CbGpPWpGaD
Dolutegravir—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000457	0.00186	CcSEcCtD
Dolutegravir—Hypersensitivity—Epirubicin—thyroid cancer	0.000445	0.00181	CcSEcCtD
Dolutegravir—Abdominal pain—Doxorubicin—thyroid cancer	0.000442	0.0018	CcSEcCtD
Dolutegravir—Asthenia—Epirubicin—thyroid cancer	0.000434	0.00176	CcSEcCtD
Dolutegravir—Pruritus—Epirubicin—thyroid cancer	0.000428	0.00174	CcSEcCtD
Dolutegravir—Diarrhoea—Epirubicin—thyroid cancer	0.000414	0.00168	CcSEcCtD
Dolutegravir—Hypersensitivity—Doxorubicin—thyroid cancer	0.000412	0.00167	CcSEcCtD
Dolutegravir—Asthenia—Doxorubicin—thyroid cancer	0.000401	0.00163	CcSEcCtD
Dolutegravir—Dizziness—Epirubicin—thyroid cancer	0.0004	0.00162	CcSEcCtD
Dolutegravir—Pruritus—Doxorubicin—thyroid cancer	0.000396	0.00161	CcSEcCtD
Dolutegravir—Vomiting—Epirubicin—thyroid cancer	0.000384	0.00156	CcSEcCtD
Dolutegravir—Diarrhoea—Doxorubicin—thyroid cancer	0.000383	0.00156	CcSEcCtD
Dolutegravir—Rash—Epirubicin—thyroid cancer	0.000381	0.00155	CcSEcCtD
Dolutegravir—Dermatitis—Epirubicin—thyroid cancer	0.000381	0.00155	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—HPGD—thyroid cancer	0.000379	0.00241	CbGpPWpGaD
Dolutegravir—Headache—Epirubicin—thyroid cancer	0.000379	0.00154	CcSEcCtD
Dolutegravir—Dizziness—Doxorubicin—thyroid cancer	0.00037	0.0015	CcSEcCtD
Dolutegravir—Nausea—Epirubicin—thyroid cancer	0.000359	0.00146	CcSEcCtD
Dolutegravir—Vomiting—Doxorubicin—thyroid cancer	0.000356	0.00145	CcSEcCtD
Dolutegravir—Rash—Doxorubicin—thyroid cancer	0.000353	0.00143	CcSEcCtD
Dolutegravir—Dermatitis—Doxorubicin—thyroid cancer	0.000352	0.00143	CcSEcCtD
Dolutegravir—Headache—Doxorubicin—thyroid cancer	0.00035	0.00142	CcSEcCtD
Dolutegravir—Nausea—Doxorubicin—thyroid cancer	0.000332	0.00135	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—TPR—thyroid cancer	0.000218	0.00138	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PRKAR1A—thyroid cancer	0.000214	0.00136	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—SLC5A5—thyroid cancer	0.000163	0.00103	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—RXRA—thyroid cancer	0.000137	0.000869	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PPARG—thyroid cancer	8.65e-05	0.000549	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PTGS2—thyroid cancer	6.81e-05	0.000432	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PTEN—thyroid cancer	5.94e-05	0.000376	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—AKT1—thyroid cancer	3.42e-05	0.000217	CbGpPWpGaD
